Transgenomic MX-ICP Panels for RAS, PIK3CA Analysis

Transgenomic has launched MX-ICP Ras Analysis and MX-ICP PIK3CA Analysis, cancer panels based on the company's multiplexed ICE-COLD PCR technology.

The MX-ICP RAS Analysis panel tests for relevant mutations in certain actionable genes, including KRAS and NRAS exons 2, 3 and 4. These genes are included in current colorectal cancer treatment guidelines as important markers to detect reduced CRC tumor sensitivity to anti-EGFR antibody therapy.

The MX-ICP PIK3CA Analysis panel tests for mutations in the PIK3CA gene in colorectal cancer and non-small cell lung cancer patients. Transgenomic has an exclusive license to test for the PIK3CA gene, which is available as a single gene test and is also included in the company's MX-ICP NSCLC Analysis panel. This gene is of interest since there are a number of clinical trials underway to determine the effectiveness of PIK3 inhibitors and the related mTOR inhibitor drug class as treatments for lung and colorectal cancer.

Both tests are available through Transgenomic's CLIA laboratory.